Also trades as: 0JDI.L (LSE) · $vol 0M
IONS NASDAQ
Ionis Pharmaceuticals, Inc.
1W: -3.2%
1M: -3.5%
3M: -18.6%
YTD: -44.8%
1Y: -38.0%
3Y: -4.8%
5Y: +40.5%
$43.96
+0.54 (+1.24%)
Weekly Expected Move ±5.4%
$38
$41
$43
$45
$48
Credit Risk of going bust: higher than 52% of companies Debt: 24.9% of company value Bonds: $115.2M held by 65 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.31B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.31B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
3 bullish
0 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
FDA unveils rare disease initiative to enhance therapy development
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
These ten healthcare stocks posted the biggest one-month losses
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
NewEdge Advisors LLC Sells 16,964 Shares of Ionis Pharmaceuticals, Inc. $IONS
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Roche, Ionis succeed in late-stage trial for kidney disease therapy
Ionis gains on late-stage trial results for ulefnersen in ALS
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Cathie Wood's weekly recap: buys $25M of CoreWeave, trims $40M in Bitcoin ETF
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Bank of America Corp DE Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Novartis scraps ALS therapy after mid-stage trial setback
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
California State Teachers Retirement System Boosts Holdings in Ionis Pharmaceuticals, Inc. $IONS
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback
Novartis facing board change threat from shareholder following trial failures
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
At a glance: stocks gapping down premarket
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Ionis Pharmaceuticals falls after Pelacarsen fails key Phase 3 heart trial
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis gains approval of zilganersen for Alexander disease
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Bank of New York Mellon Corp Takes $43.01 Million Position in Ionis Pharmaceuticals, Inc. $IONS
ADAR1 Capital Management LLC Acquires Shares of 166,286 Ionis Pharmaceuticals, Inc. $IONS
ADAR1 Capital Management LLC Acquires Shares of 166,286 Ionis Pharmaceuticals, Inc. $IONS
Breakfast News: A Conversation With Ionis CEO
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
Ionis (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals GAAP EPS of -$0.69 beats by $0.38, revenue of $268M beats by $77.91M
Here are the major earnings before the open Wednesday
Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline
Amova Asset Management Americas Inc. Has $6.13 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Cathie Wood Just Bet Big on This Biotech Stock
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
Reasons Why Investors Should Consider Betting on PTC Stock Now
Ionis extends losses as Roche scraps two partnered studies
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
AstraZeneca tumbles as heart drug trial misses main efficacy goal
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Citi's picks and pans for H2 '26: REITs, tech, consumer, health
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis, Recordati inks ex-U.S. license deal for Zilganerse
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Why Is Biogen Stock Falling Thursday?
GSK Targets China's Hepatitis B Market Through New Deal
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B
Ionis (IONS) Q1 2026 Earnings Call Transcript
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Earnings Scheduled For April 29, 2026
Ionis Pharmaceuticals beats top-line and bottom-line estimates; introduces FY26 outlook
Ionis Pharmaceuticals Q1 2026 Earnings Preview
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Assetmark Inc.
Ionis (IONS) Q4 2025 Earnings Transcript
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Aberdeen Group plc
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
When Insider Selling Is a Good Thing: 2 Stocks to Watch